Achieve Life Sciences, Inc. financial data

Symbol
ACHV on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
22722 29 Th Dr. Se, Suite 100, Seattle, Washington
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ONCOGENEX PHARMACEUTICALS, INC. (to 7/31/2017), SONUS PHARMACEUTICALS INC (to 8/7/2008)
Latest financial report
Q1 2024 - May 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 272 % +50.8%
Debt-to-equity 131 % -64.8%
Return On Equity -177 % +76.8%
Return On Assets -76.6 % +52.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.3M shares +91%
Common Stock, Shares, Outstanding 34.3M shares +91%
Entity Public Float 90.8M USD +92.5%
Common Stock, Value, Issued 103K USD +18.4%
Weighted Average Number of Shares Outstanding, Basic 25M shares +39.8%
Weighted Average Number of Shares Outstanding, Diluted 25M shares +39.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.1M USD -58.1%
General and Administrative Expense 11.6M USD +5.92%
Costs and Expenses 24.7M USD -41.5%
Nonoperating Income (Expense) -2.66M USD -64.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -29.8M USD +29.6%
Net Income (Loss) Attributable to Parent -27.3M USD +37.6%
Earnings Per Share, Basic -1.26 USD/shares +65.9%
Earnings Per Share, Diluted -1.26 USD/shares +65.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 66.4M USD +302%
Assets, Current 67.7M USD +272%
Property, Plant and Equipment, Net 13K USD +225%
Operating Lease, Right-of-Use Asset 51K USD -53.2%
Goodwill 1.03M USD 0%
Assets 70M USD +237%
Accounts Payable, Current 373K USD -64.9%
Employee-related Liabilities, Current 864K USD +15.7%
Liabilities, Current 20.6M USD +1.34%
Operating Lease, Liability, Noncurrent 6K USD -91.3%
Liabilities 20.6M USD +1.07%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4K USD 0%
Retained Earnings (Accumulated Deficit) -172M USD -18.8%
Stockholders' Equity Attributable to Parent 49.5M USD +11064%
Liabilities and Equity 70M USD +237%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.29M USD +36.3%
Net Cash Provided by (Used in) Financing Activities 56.1M USD +119283%
Net Cash Provided by (Used in) Investing Activities -21K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 34.3M shares +91%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 50.8M USD
Deferred Tax Assets, Valuation Allowance 73.2M USD +11.7%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 73.6M USD +11.6%
Payments to Acquire Property, Plant, and Equipment 21K USD
Property, Plant and Equipment, Gross 256K USD -15.5%
Operating Lease, Liability, Current 53K USD -8.62%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 48.9M USD +12.6%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 761K USD 0%
Operating Lease, Payments 58K USD -4.92%
Amortization of Intangible Assets 200K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 346K USD -12%
Interest Expense 3.09M USD +54.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%